<DOC>
	<DOCNO>NCT03074214</DOCNO>
	<brief_summary>ST-elevation myocardial infarction ( STEMI ) serious health threaten population . PCI , timely restore blood flow ischemic myocardium , well-proved measure STEMI management . However , process restoration induce injury . The phenomenon define ischemia/reperfusion ( I/R ) injury . The study indicate I/R injury account 50 % final myocardial infarct size . However , previous attempt target know mediator myocardial I/R injury patient disappointing , leading call reevaluation factor affect myocardial I/R injury [ 1 ] . Arginine vasopressin ( AVP ) , response acute illness , unstable clear rapidly circulation . However , copeptin , C-terminal portion provasopressin , release equimolar amount AVP easy determine . So , copeptin surrogate marker AVP secretion . Recently , copeptin find serve potential prognostic biomarker heart failure acute myocardial infarction ( AMI ) . AMI activate AVP axis , causative role evolution heart failure . Increasing copeptin show correlate myocardial remodeling , mortality morbidity . In patient STEMI , myocardial infarct size strong outcome predictor LV function , relate LV remodeling , often indicate significant bad prognosis AMI . As gold standard characterisation cardiac structure function , cardiac magnetic resonance ( CMR ) parameter serve surrogate end point clinical trial STEMI . We hypothesise plasma copeptin value , test PCI , related myocardial infarct size , myocardial function outcome baseline 6 month follow-up assess CMR patient STEMI .</brief_summary>
	<brief_title>Prognostic Value Copeptin Infarct Size Prognosis Patients With ST-elevation Myocardial Infarction</brief_title>
	<detailed_description>Acute myocardial infarction ( AMI ) major concern public health China . Ischemia/reperfusion injury cripple treatment effect reperfusion management , increase final myocardial infarct size . Copeptin related prognosis heart failure AMI , may potential prognostic biomarker myocardial infarct size , myocardial function outcomes patient STEMI undergo PCI.This study enroll consecutive STEMI patient undergo PCI , meet inclusion exclusion criterion , large-scale hospital Northeast China . After obtain informed consent , blood sample draw time , immediately , 3 day PPCI . They collect EDTA tube centrifuge 10 min 2000 g within 0.5 h. Plasma store −80°C analysis . Plasma copeptin concentration determine commercially available automate immunofluorescent assay ( R &amp; D Systems Inc. Minneapolis , USA ) . And information symptom , functioning , quality life , medical care , demographic characteristic , medical history , clinical feature , diagnostic test , medication procedural data also collect . Baseline CMR perform 3-5 day PPCI . All scan perform 3.0 Tesla scanner . At 1 month , 3 month , 12 month discharge , participant receive follow-up phone . At 6 month discharge , participant return clinic follow visit , face-to-face interview conduct get information clinical event , symptom , functioning , quality life , medical care recovery period . Follow-up CMR scan conduct . Follow-up blood sample draw test copeptin . Sample Size Calculation A study size analysis perform use PASS ( version 11.0.4 , 2011 , NCSS , LLC , USA ) . In previous study , 90-day primary composite end point all-causes death , ventricular fibrillation , cardiogenic shock , congestive heart failure require rehospitalization emergency room visit 90 day 10.3 % STEMI patient undergo PCI . [ 1 ] Although available data detect clinically relevance copeptin prognosis STEMI patient undergo PCI limit , previous study demonstrate high concentration ( quartile 4 vs. quartile 1 3 ) copeptin identify increase risk CV death HF ( HR:2.80,95 % CI:2.24-3.51 , P &lt; 0.001 ) . [ 2 ] When ratio groups1 2 3:1 , overall sample size 275 subject , 207 group 1 68 group 2 , achieve 90 % power 0.0500 significance level detect difference 0.1280 0.9290 0.8010 -- proportion survive group 1 2 , respectively . The proportion patient lose follow 0.1000 .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1. chest pain present less 12 hour onset pain time catheterization ; 2. significant STsegment elevation ( least 0.1 mV two standard lead least 0.2 mV two contiguous precordial lead ) new leave bundle branch block ; 3. receive primary PCI . 1 . Patients condition STEMI could cause increase copeptin level , renal dysfunction ( eGFR &lt; 30 ml/min ) , liver failure , respiratory tract infection , stroke , sepsis , hyponatremia ( Serum sodium concentration &lt; 135mmol/L ) , central diabetes insipidus malignancy ; 2 . Patients contraindication perform cardiac magnetic resonance ; 3 . Patients cardiogenic shock ( Killip class IV ) ; 4 . Patients reperfusion therapy fail ; 5 . Patients refer emergency coronary artery bypass grafting ( CABG ) view unfavourable coronary anatomy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>copeptin</keyword>
	<keyword>myocardial infarct size</keyword>
	<keyword>prognosis</keyword>
	<keyword>ST-elevation myocardial infarction</keyword>
	<keyword>percutaneous coronary intervention</keyword>
</DOC>